Loading...
•
Sep 30, 2024
Azenta Q4 2024 Earnings Report
Azenta reported mixed Q4 2024 results with revenue down slightly but growth in core segments and margin expansion.
Key Takeaways
Azenta's Q4 2024 revenue was $170 million, a 1% decrease year-over-year. However, the combined Sample Management Solutions and Multiomics businesses grew 5% organically. The company reported a diluted EPS from continuing operations of ($0.10) and a non-GAAP diluted EPS of $0.18. They are pursuing the sale of B Medical Systems.
Revenue decreased by 1% year-over-year to $170 million.
Combined Sample Management Solutions and Multiomics businesses grew 5% organically.
Non-GAAP diluted EPS was $0.18, compared to $0.13 in the prior year.
The company announced plans to sell B Medical Systems.
Azenta
Azenta
Azenta Revenue by Segment
Revenue by Segment
Sample Management Solutions Revenue
CapyFin.comMultiomics Revenue
CapyFin.com Forward Guidance
Azenta expects total organic revenue growth in the range of 3% to 5% for fiscal year 2025, excluding B Medical Systems. Adjusted EBITDA margin expansion is expected to be approximately 300 basis points relative to fiscal 2024.
Positive Outlook
- Total organic revenue is expected to grow in the range of 3% to 5% relative to fiscal 2024.
- Adjusted EBITDA margin expansion is expected to be approximately 300 basis points relative to fiscal 2024.
- Focus on core revenue growth in Sample Management Solutions and Multiomics businesses.
- Commitment to meaningfully expand margins.
- Renewed focus on free cash flow.
Challenges Ahead
- Azenta does not provide forward-looking guidance on a GAAP basis.
- Inherent difficulty in accurately forecasting the occurrence and financial impact of the various adjusting items.
- Adjustments include transformation costs, restructuring charges, costs related to acquisitions and divestitures costs, governance-related matters, goodwill and intangible impairments, and other gains and charges.
- These adjustments are not representative of the normal operations of the business.
- Company is unable to provide a quantitative reconciliation of forward-looking non-GAAP measures to the most directly comparable forward-looking GAAP measure, without unreasonable effort.
Revenue & Expenses
Visualization of income flow from segment revenue to net income